Annual report pursuant to Section 13 and 15(d)

REVENUES (Tables)

v3.22.4
REVENUES (Tables)
12 Months Ended
Dec. 31, 2022
REVENUES  
Schedule of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

Year Ended December 31,

​

​

2022

    

2021

    

2020

Product sales:

​

​

​

​

​

​

​

​

​

Gross product sales

​

$

108,523

​

$

81,186

​

$

76,470

Discounts and allowances

​

​

(31,805)

 

​

(18,176)

 

​

(14,774)

Total product sales, net

​

​

76,718

​

​

63,010

​

​

61,696

Revenues from collaborations:

​

​

​

​

​

​

​

​

​

License revenues

​

​

7,932

​

​

70,553

​

​

40,358

Development milestones

​

​

25,000

 

​

1,875

 

​

2,100

Research and development services and others

​

​

6,092

 

​

3,298

 

​

4,467

Total revenues from collaborations

​

​

39,024

​

​

75,726

​

​

46,925

Government contract

​

​

4,500

​

​

10,500

​

​

—

Total revenues

​

$

120,242

​

$

149,236

​

$

108,621

​

Schedule of product revenue allowance and reserve categories

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Chargebacks,

​

Government

​

​

​

​

​

​

Discounts and

​

and Other

​

​

​

​

​

​

Fees

​

Rebates

​

Returns

​

Total

Balance as of January 1, 2022

    

$

3,404

​

$

2,494

​

$

2,017

​

$

7,915

Provision related to current period sales

​

​

23,488

​

​

5,901

​

​

1,514

​

​

30,903

Credit or payments made during the period

​

​

(20,679)

​

​

(5,759)

​

​

(235)

​

​

(26,673)

Balance as of December 31, 2022

 

$

6,213

​

$

2,636

​

$

3,296

​

$

12,145

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Chargebacks,

​

Government

​

​

​

​

​

​

​

​

Discounts and

​

and Other

​

​

​

​

​

​

​

​

Fees

​

Rebates

​

Returns

​

Total

Balance as of January 1, 2021

    

$

2,461

 

$

2,115

​

$

1,489

​

$

6,065

Provision related to current period sales

​

​

10,731

​

​

5,036

​

​

1,021

​

​

16,788

Credit or payments made during the period

​

​

(9,788)

​

​

(4,657)

​

​

(493)

​

​

(14,938)

Balance as of December 31, 2021

 

$

3,404

​

$

2,494

​

$

2,017

​

$

7,915

Schedule of revenues from product sales disaggregated by customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more (wherein * denotes less than 10%) of the total net product sales and revenues from collaborations:

​

​

​

​

​

​

​

​

​

​

​

​

Year Ended December 31,

​

​

2022

    

2021

​

2020

McKesson Specialty Care Distribution Corporation

​

​

31%

​

​

20%

​

​

23%

Kissei

​

​

24%

​

​

*

​

​

—

Cardinal Healthcare

​

​

19%

​

​

*

​

​

*

ASD Healthcare and Oncology Supply

​

​

17%

​

​

17%

​

​

30%

Lilly

​

​

*

​

​

48%

​

​

—

Grifols

​

​

*

​

​

*

​

​

41%